Sanofi selects Recursion drug candidate, triggering $10 million payment

Recursion said Sanofi selected the first development candidate from their AI-driven drug discovery collaboration, triggering a $10 million milestone payment. The potential oral treatment targets two proteins implicated in inflammatory diseases. Sanofi will fund and lead further development and commercialization, with Phase 1 trials planned for 2027. Recursion said the selection ends its operational obligations for this candidate. The milestone brings total upfront and milestone payments under the collaboration to $144 million; additional milestones and sales royalties depend on further progress.